RECRUITINGOBSERVATIONAL
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
About This Trial
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Who May Be Eligible (Plain English)
Who May Qualify:
- Migraine diagnosis according to ICHD-III.
- Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
- Signature of willing to sign a consent form.
Who Should NOT Join This Trial:
- Presence of headache different from migraine.
- Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Migraine diagnosis according to ICHD-III.
* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
* Signature of informed consent.
Exclusion Criteria:
* Presence of headache different from migraine.
* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Treatments Being Tested
DRUG
CGRP antibody or gepant
Patients will start anti-CGRP or its receptor antibody or gepants
Locations (20)
University of Miami, Miller School of Medicine
Miami, Florida, United States
FLENI
Buenos Aires, Argentina
Pontificia Universidad Católica de Chile
Santiago, Chile
Neuromedica
Medellín, Colombia
Special Hospital for Orthopedics and Rehabilitation "Martin Horvat" Rovinj-Rovigno
Rovinj, Croatia
Charité Universitätsmedizin Berlin
Berlin, Germany
LMU University Hospital
München, Germany
University of L'Aquila
L’Aquila, Italy
University of Modena and Reggio Emilia
Modena, Italy
National Neurological Institute C. Mondino Foundation
Pavia, Italy
IRCCS San Raffaele
Roma, Italy
Universiti Putra Malaysia
Serdang, Selangor, Malaysia
Neuroclinic Norway
Lillestrøm, Norway
Wrocław Medical University
Wroclaw, Poland
Hospital Santa Maria Lisbon
Lisbon, Portugal
Germans Trias i Pujol Hospital
Badalona, Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Barcelona, Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Fundació Sanitària Mollet
Mollet del Vallès, Barcelona, Spain
Hospital de Viladecans
Viladecans, Barcelona, Spain